Immunotherapy: Equal Triumphs for Senior and Young Cancer Patients

With advancing age, the immune system often diminishes; nevertheless, a recent examination demonstrates that senior cancer patients may respond as proficiently to immunotherapy as their younger counterparts. Notably, some older patients exhibit even superior outcomes. Dr. Daniel Zabransky from Johns Hopkins University emphasizes the importance of refining age-appropriate therapies. Continued investigation aims to pinpoint biomarkers to elevate immunotherapy effectiveness across various age groups, striving to customize cancer treatment strategies for the elderly.